Propanc Biopharma (PPCB) Payables (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Payables of $957483.0 for Q4 2025, down 31.19% year-over-year from $1.4 million in Q4 2024, and down 10.69% quarter-over-quarter from $1.1 million in Q3 2025.
Propanc Biopharma (PPCB) Payables (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Payables for 15 consecutive years, with $957483.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Payables fell 31.19% year-over-year to $957483.0; the TTM figure through Dec 2025 stood at $957483.0 (down 31.19% YoY), while the FY2025 annual figure was $1.8 million, up 26.44% from the prior year.
- Payables fell to $957483.0 in Q4 2025 per PPCB's latest filing, from $1.1 million in the prior quarter.
- Across five years, Payables topped out at $1.8 million in Q2 2025 and bottomed at $826184.0 in Q3 2021.
- Historically, Payables has averaged $1.1 million across 5 years, with a median of $994615.0 in 2021.
- Annual changes were most pronounced in 2024 — Payables soared 46.68% — and 2025, when it tumbled 31.19%.
- Propanc Biopharma's Payables stood at $920692.0 in 2021, then increased by 7.19% to $986895.0 in 2022, then soared by 30.68% to $1.3 million in 2023, then increased by 7.89% to $1.4 million in 2024, then sank by 31.19% to $957483.0 in 2025.
- Business Quant data shows PPCB's Payables at $957483.0 in Q4 2025, $1.1 million in Q3 2025, and $1.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 957,483.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 957,483.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 966,718.00 |
| Mar 31, 2023 | 918,195.00 |
| Dec 31, 2022 | 986,895.00 |
| Sep 30, 2022 | 899,225.00 |
| Jun 30, 2022 | 943,023.00 |
| Mar 31, 2022 | 967,213.00 |
| Dec 31, 2021 | 920,692.00 |
| Sep 30, 2021 | 826,184.00 |
| Jun 30, 2021 | 1.00 Mn |
| Mar 31, 2021 | 950,131.00 |